Home › Malattie cardiovascolari › Mississippi › Tupelo
Studi clinici su Malattie cardiovascolari a Tupelo, MS
6 studi su Malattie cardiovascolari cercano partecipanti presso sedi a Tupelo e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
In reclutamentoFase 4
- Cardiology Associates of North Mississippi, Tupelo
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
In reclutamentoFase 3
- Clinical Trial Site, Tupelo
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
In reclutamentoFase 3
- Cardiology Associates Research LLC, Tupelo
SPYRAL GEMINI Pilot Study
In reclutamento
- North Mississippi Medical Center, Tupelo
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
In reclutamento
- North Mississippi Medical Center, Tupelo
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
In reclutamento
- Cardiology Associates Research, LLC, Tupelo
- Cardiology Associates Research, LLC, Tupelo
Studi su Malattie cardiovascolari in altre città
- Boston, MA37 studi
- New York City, NY33 studi
- Washington, DC28 studi
- Houston, TX24 studi
- Dallas, TX23 studi
- Atlanta, GA22 studi
- Cleveland, OH22 studi
- Chicago, IL21 studi
- Philadelphia, PA21 studi
- Pittsburgh, PA20 studi
- St. Louis, MO20 studi
- Nashville, TN18 studi
Altri studi a Tupelo
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.